Other
Cash and cash equivalents, end of period
Synopsys Cash and cash equivalents, end of period decreased by 26.2% to $2.13B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 41.7%, from $3.66B to $2.13B. Over 3 years (FY 2022 to FY 2025), Cash and cash equivalents, end of period shows an upward trend with a 26.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ4 2024
Last reportedQ1 2026
Metric ID:
other_cash_cash_equivalents_restricted_cash_and_restrict_5675e1Historical Data
13 periods
| Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.42B | $1.55B | $1.69B | $1.44B | $1.12B | $1.51B | $1.86B | $3.90B | $3.66B | $14.12B | $2.53B | $2.89B | $2.13B |
| QoQ Change | — | +8.9% | +9.2% | -14.6% | -22.2% | +34.8% | +23.0% | +109.7% | -6.2% | +286.1% | -82.1% | +14.3% | -26.2% |
| YoY Change | — | — | — | +1.5% | — | -2.2% | +10.2% | +170.5% | +226.2% | +834.3% | +36.2% | -25.8% | -41.7% |
Range$1.12B – $14.12B
CAGR+14.6%
Avg YoY Growth+134.4%
Median YoY Growth+10.2%
Cash and cash equivalents, end of period at Other Companies
Frequently Asked Questions
- What is Synopsys's cash and cash equivalents, end of period?
- Synopsys (SNPS) reported cash and cash equivalents, end of period of $2.13B in Q4 2025.
- How has Synopsys's cash and cash equivalents, end of period changed year-over-year?
- Synopsys's cash and cash equivalents, end of period decreased by 41.7% year-over-year, from $3.66B to $2.13B.
- What is the long-term trend for Synopsys's cash and cash equivalents, end of period?
- Over 3 years (2022 to 2025), Synopsys's cash and cash equivalents, end of period has grown at a 26.8% compound annual growth rate (CAGR), from $1.42B to $2.89B.